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To Screen or Not to Screen. How do we Decide on 
Which Cancer Screening Activities to Embark 
Upon? 
J.D.F. Habbema and G. J. van Oortmarssen 
THE PUBLIC HEALTH PERSPECTIVE 
SCREENING, i.e. early detection before a clinical diagnosis is 
made on the basis of symptoms, has been proposed for cancers 
at many sites (see [l] for an overview). The goal of population 
screening is to reduce the burden of the cancer in terms of 
morbidity and mortality. In this respect, it is just one of several 
possible interventions and should be compared with the other 
alternatives: primary prevention, early case finding, treatment, 
rehabilitation and terminal care. In judging screening, however, 
adverse ffects hould be considered especially carefully, because 
inevitably a number of apparently healthy persons will be 
subjected to medical tests, and possibly to treatment, with no 
real long-term improvement in health or longevity. 
The comparison should be based primarily on the favourable 
and adverse effects and risks of the interventions. In making 
choices about (re)allocation of funds between types of inter- 
vention, their costs should be weighted against their health 
effects. Cost-effectiveness analysis, cost-utility analysis and 
cost-benefit analysis are the methodologies which may be applied 
in investigating the decision problems [2-4]. A consideration 
that is often overlooked is that of (re)distribution of health over 
the population. For example, cervical cancer is typically a disease 
of women in lower socioeconomic strata, while breast cancer is 
one of the few examples of a disease that occurs more frequently 
in people in higher socioeconomic strata. In view of the present 
inequality in the distribution of health demonstrated in many 
countries, cervical cancer screening should deserve some extra 
attention, but also taking into account that it has a less favourable 
cost-effectiveness ratio than breast cancer screening. 
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AN ILLUSTRATION OF BREAST CANCER SCREENING 
Table 1 shows the predicted favourable and adverse ffects of 
two-yearly breast cancer screening of women aged 50-70 years 
in the Netherlands [5]. Nationwide screening between 1990 and 
2017 is expected to result in a reduction of 6000 breast cancer 
deaths and a gain of 16 500 years of life per million screening 
examinations. 
Adjustment of the years of life because of changes in quality 
of life brought about by other effects of screening will have only 
a small impact: 16 000 quality-adjusted years of life would be 
gained. 
Health effects hould be considered in relation to the resources 
required for establishing those effects. For example, the total 
cost of 15.8 million screenings for breast cancer in the 27-year 
period will be 489 million ECU (1 ECU = 2.30 Dfl), i.e. 31 
ECU per examination. These costs are partly compensated, since 
screening will result in a decrease in the costs of management of 
breast cancer (-249 million ECU), mainly because of the 
Table 1. Favourable and adverse effects of breast cancer screening 
in the Netherlands: implications for diffmences in quality-adjusted 
years of life per million screening examinations (no discounting) 
Number Quality-adjusted 
years of life 
Screening examinations 1000 000 - 115 
Years of life gained 16 500 + 15700 
Advanced and terminal cancer 1080 + 730 
Lead time (earlier diagnosis) 17500 - 500 
Breast conserving therapy 
instead of mastectomy 750 + 40 
Others + 145 
Total 16 000 
prevention of advanced disease. Women who benefit from Thirdly, recommending a screening test for specific age 
screening will, however, have other medical costs during their groups (or other risk categories) will always raise the demand 
additional years of life. An important complication is that, in from other groups. Experience with cervical cancer screening 
general, costs and adverse effects occur long before favourable shows that centrally organised screening with a test that does not 
effects and savings are seen. Time preference is taken into require specialised equipment results in large-scale opportunistic 
account by using discount rates, calculating present values for screening outside the programme. In the case of cervical cancer, 
effects, costs and the cost-effectiveness ratio (Table 2). such opportunistic screening is inefficient, since it involves 
The time lag between costs and effects may differ considerably predominantly women who are too young and intervals between 
between screening programmes, e.g. those for cervical cancer, tests that are too short. Coverage, quality control and opportun- 
which has a very long preclinical stage, and those for breast istic screening deserve special attention when results and con- 
cancer, which has a much shorter preclinical stage. Thus, clusions from an experimental scientific project are transferred 
discounting will influence the cost-effectiveness of cervical can- to a routine population screening service. 
cer screening in a more unfavourable way than for breast cancer 
screening. VERIFYING THE EFFECTIVENESS OF SCREENING 
The outcomes of a cost-effectiveness tudy are highly depen- A screening test must undergo rigorous testing and evaluation 
dent on the specific assumptions on the various aspects of the before it can be judged to be eligible for mass implementation. 
problem. Hence, results of a sensitivity analysis, in which Basic criteria for judging a screening test were specified by 
assumptions about all aspects are varied in order to investigate Wilson and Jungner in 1966 [6]. Only a small number of tests 
their impact on the outcomes, are more informative than just the fuliil the minimal requirements for sensitivity and specifity, and 
most plausible outcomes. The results of the sensitivity analysis elicit general agreement on the assessment of abnormalities and 
will indicate how robust the conclusions about the screening on the type of treatment o be used for diagnosed (pre-)invasive 
programme are. cancer. These requirements may be investigated on the basis of 
small-scale (clinical) experiments. 
REALISTIC SCENARIOS Three well-known biases (lead time, length and self-selection) 
In making predictions about the potential effects of a screening preclude final testing of a screening test in a non-randomised 
test, a number of complicating factors should not be overlooked. design. The theoretical problems of the case-control design have 
First, the coverage of the population has been found to vary been confirmed empirically [7]. The effectiveness of a screening 
considerably between countries, screening tests and risk groups test in reducing mortality and morbidity should be demonstrated 
(e.g. age). Coverage also strongly depends on the way in which in one or more population-based randomised controlled trials. 
screening is organised: highest coverage is achieved with central- The absence of evidence based on such trials for the effectiveness 
ised programmes involving an invitation scheme based on popu- of cervical cancer screening by Pap smears has always troubled 
lation registries (Nordic countries, the Netherlands). In the decision makers. 
Netherlands, a considerable drop in attendance occurred when Randomised controlled trials are, however, very costly and 
cervical cancer screening ceased to be organised centrally. they cannot solve all questions. A single trial generally allows 
Secondly, thorough quality control of all stages of the screen- only direct conclusions about the effectiveness of the specific 
ing process, i.e. of the test procedure (mamm ograms, Pap policy used and, depending on the size of the trial, about 
smear), of the interpretation of the results, and of further differences in effectiveness across age groups. Another inevitable 
assessment of women with positive results at screening, is problem is that conclusions can be drawn from a randomised 
mandatory in order to prevent high proportions of false-positive controlled trial only after some 10 years, by which time the 
and false-negative results and unnecessary, invasive diagnostic screening test or the treatment may have changed considerably. 
tests. Remarkable differences in referral rates after a positive 
mammography are found between the U.S.A. and the U.K. on CHOOSING A SCREENING POLICY 
the one hand, and Sweden, Finland and the Netherlands on the Once effectiveness has been demonstrated, further evidence 
other. Similar differences might occur within one country in the of the effectiveness in different age groups or with different 
absence of good quality control. screening intervals can be obtained from case-control studies. 
For a comprehensive valuation of screening policies (age 
Table 2. Costs and effects of breast cancer screening, the Netherlands groups, intervals, risk groups) with respect to health effects, 
(see Table 1): comparison of outcomes with and without discounting risks and costs, simulation models are powerful tools, as all 
important factors can be taken into account. The predictions 
Discount rate shown in Tables 1 and 2 were obtained using a MISCAN model 
0% 5% for breast cancer screening, which has been validated against 
data from randomised trials in Sweden and from the Dutch pilot 
Years of life gained (crude) 260 000 61000 studies [8, 91. Another MISCAN model was used to evaluate 
Quality-adjusted years of life gained 252 000 57 500 cervical cancer screening in the Netherlands: the best cost- 
I. Screening costs* 489 260 effectiveness ratio (just over 10 000 ECU per year of life gained, 
II. Costs of breast cancer management* - 249 - 58 5% discounted) was found using a programme that starts around 
III. Other medical costs* + 920 f 181 age 30 and continues up to age 70, with an interval between 
Costs (I + II) per year of life+ 920 3300 
successive screenings of about 6 years. Policies with much 
Costs (I + II) per quality-adjusted year of shorter intervals show a much less favourable balance between 
life gained+ 960 3500 benefits, risks and costs. When screening starts at a very young 
Costs (I + II + III) per year of life+ 4440 6 300 age, risks and costs increase considerably with only a small 
improvement in beneficial effects [10, 11, 121. 
*Million ECU. +ECU. The decision-orientated approach is still useful after the 
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screening test has been implemented in a population-based 
early detection programme. The results of the programme 
(participation, detection rate, stage distribution, interval can- 
cers, costs) should be carefully registered and monitored and 
can be compared with expectations made at the outset. Major 
discrepancies or new developments in diagnosis and therapy can 
be investigated by computer simulation, which will lead to 
recommendations about adaptations of the screening policy, 
conducting new pilot studies or sometimes even randomised 
controlled trials. 
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